Abgenix expands two deals

ABGX expanded deals with both Immunex (IMNX) and CuraGen (CRGN) on Tuesday. ABGX and IMNX expanded their ABX-EGF collaboration by entering a 5-year agreement to develop antibodies for cancer treatment (see BioCentury, July 31). Each company will contribute five cancer-specific antigen targets, ABGX will provide its XenoMouse technology to generate and screen human monoclonal antibodies against each target and IMNX will provide target validation and preclinical testing experience. The companies will share equally in product development and commercialization. ...